Prevalence of


Journal

International journal of cardiology
ISSN: 1874-1754
Titre abrégé: Int J Cardiol
Pays: Netherlands
ID NLM: 8200291

Informations de publication

Date de publication:
01 06 2019
Historique:
received: 23 07 2018
revised: 25 09 2018
accepted: 23 10 2018
pubmed: 10 11 2018
medline: 7 1 2020
entrez: 10 11 2018
Statut: ppublish

Résumé

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable heart muscle disease that causes sudden cardiac death in the young. Inflammatory myocardial infiltrates have been described at autopsy and on biopsy, but there are few data on the presence of myocarditis in living patients with ARVC using non-invasive imaging techniques. FDG-PET is a validated technique for detecting myocardial inflammation in clinically suspected myocarditis. We aimed to determine the prevalence of myocardial inflammation in patients with ARVC using We performed a retrospective analysis of a single centre cohort of patients with ARVC referred for FDG-PET scans between 2012 and 2017 for investigation of symptoms or suspected device infection. Sixteen patients (12 male; age 42 ± 13 years) with a definite diagnosis of ARVC were identified. Seven had positive FDG-PET scans, two of whom had cardiac sarcoidosis on endomyocardial biopsy. Of the remaining five, two carried pathogenic desmoplakin mutations. FDG uptake was found in the left ventricular myocardium in all cases. One patient also had right ventricular uptake. In this exploratory study, we show that some patients with ARVC have evidence for myocardial inflammation on FDG-PET, suggesting that myocarditis plays a role in disease pathogenesis.

Sections du résumé

BACKGROUND
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a heritable heart muscle disease that causes sudden cardiac death in the young. Inflammatory myocardial infiltrates have been described at autopsy and on biopsy, but there are few data on the presence of myocarditis in living patients with ARVC using non-invasive imaging techniques. FDG-PET is a validated technique for detecting myocardial inflammation in clinically suspected myocarditis. We aimed to determine the prevalence of myocardial inflammation in patients with ARVC using
METHODS AND RESULTS
We performed a retrospective analysis of a single centre cohort of patients with ARVC referred for FDG-PET scans between 2012 and 2017 for investigation of symptoms or suspected device infection. Sixteen patients (12 male; age 42 ± 13 years) with a definite diagnosis of ARVC were identified. Seven had positive FDG-PET scans, two of whom had cardiac sarcoidosis on endomyocardial biopsy. Of the remaining five, two carried pathogenic desmoplakin mutations. FDG uptake was found in the left ventricular myocardium in all cases. One patient also had right ventricular uptake.
CONCLUSION
In this exploratory study, we show that some patients with ARVC have evidence for myocardial inflammation on FDG-PET, suggesting that myocarditis plays a role in disease pathogenesis.

Identifiants

pubmed: 30409737
pii: S0167-5273(18)34604-7
doi: 10.1016/j.ijcard.2018.10.083
pii:
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

99-104

Informations de copyright

Copyright © 2018 Elsevier B.V. All rights reserved.

Auteurs

Alexandros Protonotarios (A)

Institute for Cardiovascular Science, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, London, UK. Electronic address: alexanderproton@gmail.com.

Eleanor Wicks (E)

Institute for Cardiovascular Science, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, London, UK; John Radcliffe Hospital, Oxford University Hospitals, Oxford, UK.

Michael Ashworth (M)

Department of Pathology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.

Edward Stephenson (E)

Barts Heart Centre, St Bartholomew's Hospital, London, UK; William Harvey Research Institute, London, UK.

Oliver Guttmann (O)

Institute for Cardiovascular Science, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Kostas Savvatis (K)

Barts Heart Centre, St Bartholomew's Hospital, London, UK; William Harvey Research Institute, London, UK.

Neha Sekhri (N)

Barts Heart Centre, St Bartholomew's Hospital, London, UK.

Saidi A Mohiddin (SA)

Barts Heart Centre, St Bartholomew's Hospital, London, UK; William Harvey Research Institute, London, UK.

Petros Syrris (P)

Institute for Cardiovascular Science, University College London, London, UK.

Leon Menezes (L)

Barts Heart Centre, St Bartholomew's Hospital, London, UK; Institute of Nuclear Medicine, University College London, London, UK; NIHR University College London Hospitals Biomedical Research Centre, UK.

Perry Elliott (P)

Institute for Cardiovascular Science, University College London, London, UK; Barts Heart Centre, St Bartholomew's Hospital, London, UK; NIHR University College London Hospitals Biomedical Research Centre, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH